Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat...


Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat consensus estimates, primarily due to a non-cash impairment charge of as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology. Gross margin also fell to 81.1%, compared to 82.3%. Read more on earnings here: Earnings Call Transcript.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs